Aptar Requests U.S. FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShield™.


Decoding Article 117 of Medical Device Regulation 2017/745 as applicable to integral drug-device combination products

Read description

Exploring the current situation, challenges & solutions

Replacing the Medical Devices Directive (MDD) 93/42/EEC, the Medical Devices Regulation (MDR) 2017/745 will provide greater safety for patients and better transparency for all stakeholders. Manufacturers need to comply for both existing and new technologies. This includes drug-device combination products that form a non-reusable, single, integral product exclusively used to administer the medicinal product, under the requirements of Article 117. Article 117 introduces the notion of risk-classification, and accordingly to involve a Notified Body as a new stakeholder in the medicinal product’s Marketing Authorization Application (MAA) process in Europe.

This webinar explains the Article 117 requirements for single integral drug-device combination products, providing an overview of the current situation and the challenges ahead, from both the Authorities’ and Industry perspectives. Back in 2019 the European Medicines Agency (EMA) published in draft guidance and Q&A; however, many questions remain, which we review during this webinar. The EMA is proposing a collaborative workshop across all stakeholders to help clarify Article 117 implementation and translate this into a final EMA guideline. This multi-stakeholder workshop is currently postponed due to the COVID-19 pandemic, so we share our current view on how to get prepared for Article 117.

Viewers will gain a greater understanding of the impact of MDR’s Article 117 on all stakeholders involved in a single integral drug-device combination product’s development, the approval process and lifecycle management.

Presented by

Krystel Limouzin Global Regulatory Affairs Director, Aptar Pharma
Krystel Limouzin is an engineer, having received her engineering degree in pharmaceutical sciences from the faculty of pharmacy of Montpellier, France, with a master’s degree in regulatory affairs from the faculty of pharmacy of Châtenay-Malabry, Paris, France. She has over 20 years of regulatory affairs experience in pharma, medical devices and container-closure systems/combination products environments. She started her regulatory affairs carreer in national and international pharmaceutical companies, and then moved to the container-closure systems and parenteral drug-delivery devices sectors. In the past years she was in charge of global medical regulatory affairs for an international medical company, and more recently in 2019, she joined Aptar Pharma as Global Regulatory Affairs Director, to manage the regulatory affairs teams and activities for Aptar Pharma globally.
Andrew Wood Associate Director – Regulatory Affairs, Aptar Pharma
Andrew Wood has more than thirty years’ experience in the OINDP (Orally Inhaled and Nasal Drug Product) industry. Initially working as Quality Manager for a device manufacturing company, he then spent many years with a major pharmaceutical company as device technical support for development and launch of inhalation combination products. He joined Aptar twelve years ago as Associate Director for Regulatory Affairs, supporting many clients through regulatory approvals of OINDPs in all world markets.
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

May 26, 2020 3PM London / 10AM New York 60 min
Watch now
Presented by
Krystel Limouzin Global Regulatory Affairs Director, Aptar Pharma
Andrew Wood Associate Director – Regulatory Affairs, Aptar Pharma
Read more
Key Learning Objectives
  • Baseline knowledge on MDR’s Article 117 requirements for single integral drug-device combination products
  • Overview of the current situation and challenges from EU regulators’ and Industry’s points of view
  • Current Industry preparation for the EMA multi-stakeholder workshop
  • Food for thought to internally plan for Article 117 implementation
Do you have questions about this webinar ?
Contact us